

Curriculum Vitae

Dr Elaine Sullivan

Academic degree: PhD in Molecular Biology and Virology, University of Edinburgh

Occupation: Non-Executive Director at the IP Group plc, hVIVO plc and Nykode Therapeutics ASA

Place of residence: Leicestershire/UK

Personal data

Year of birth: 1961

Nationality: British

Member of the Supervisory Board of Evotec SE

First appointment to the Supervisory Board of Evotec SE: 19 June 2015

Last re-election: 19 June 2019

End of term: End of Annual General Meeting 2024

Education

1979 – 1983 University of Glasgow
Bachelor

1983 – 1987 University of Edinburgh
Conferral of a doctorate (PhD)

Professional career

1995 – 2010 AstraZeneca AB
Various positions, most recently Vice-President R&D, New Opportunities

2011 – 2014 Vice President Global External Research and Development at Eli Lilly & Company, Inc.

2015 – 2019 CEO of Carrick Therapeutics, Ltd.

April 2020 – May 2021 CEO of Curadh Pharmaceuticals



October 2021 – December 2022

CEO of KELTIC Pharma Therapeutics Ltd.

Since January 2023

Non-Executive Director at the IP Group plc, hVIVO plc, Active Bitotech AB, and Nykode Therapeutics ASA

Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises

Zealand Pharma A/S, DK

Member of the Supervisory Board

Active Biotech AB, SE

Non-Executive Director

IP Group plc, UK

Non-Executive Director

hVIVO plc (formerly Open Orphan), UK Non-Executive Director

Nykode Therapeutics ASA, NO

Non-Executive Director

Other significant activities besides the Supervisory Board mandate

n/a

Relevant knowledge, skills and experience

Since January 2023, Dr Elaine Sullivan is Non-Executive Director at the IP Group plc, hVIVO plc, Active Bitotech AB, and Nykode Therapeutics ASA. From October 2021 until December 2022, Dr Elaine Sullivan was CEO of Keltic Pharma Therapeutics Ltd. Since April 2020, she was CEO of Curadh Pharmaceuticals. From 2015 to 2019, Dr Sullivan was Chief Executive Officer of Carrick Therapeutics Ltd, a European oncology company, which she continues to support as Executive Entrepreneur and Advisor to the Board of Directors. Elaine Dr Sullivan has worked as part of top management teams in R&D at Eli Lilly and AstraZeneca.

She has over 25 years of international experience working in the pharmaceutical industry in the USA and the UK. From 2011 to 2014, she served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, IN, USA, where she led a global workforce delivering access to business-critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly's Capital Fund partners.

Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca from 1995 until 2010, including Vice President R&D, New Opportunities, from 2007 to 2010. In this role, she established and led AstraZeneca's virtual Therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic.

During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer, ophthalmology and respiratory and inflammation. Furthermore, she has particular expertise in origination, development and execution of innovative partnerships. Since July 2015, Dr Elaine Sullivan has been serving as Non-executive Director of the IP Group plc. Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor's degree in Molecular Biology from the University of Glasgow, UK.



Due to her extensive knowledge of various aspects of drug discovery and development and her focus on developing external partnerships including spinouts, joint ventures, and strategic alliances Dr Sullivan ideally complements the future Supervisory Board of Evotec SE.

Personal or business relationships in accordance with items C.6 to C.12 of the German Corporate Governance Code

Dr Elaine Sullivan (the former CEO of Carrick Therapeutics Ltd) is independent. Evotec SE holds approximately 4.5% of the shares in Carrick Therapeutics Ltd., and it is not a significant partner of Carrick Therapeutics Ltd. at present. Therefore, for two reasons there is no conflict of interest that could hinder the position of independence:

(1) Evotec SE's participation rights in Carrick Therapeutics Ltd. are exercised by the Management Board of Evotec SE on its own responsibility pursuant to section 76 paragraph 1 of the German Stock Corporation Act (AktG). In particular, a member of the Supervisory Board has no influence on the voting on the resolutions of the shareholders of Carrick Therapeutics Ltd. (e.g. on any formal approval).

(2) There is also no intersecting executive body position, nor are there any other significant connections to members of the company's Management Board through their involvement in other companies or organisations.

Latest update: December 2023